domenica, 3 maggio 2026

Notizie Newsletter

28 Novembre 2019

FDA Grants Priority Review to Pemigatinib for FGFR2+ Cholangiocarcinoma

November 27, 2019 - The FDA has granted a priority review to a new drug application (NDA) for pemigatinib as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements. The designation is based ...
Leggi tutto

26 Novembre 2019

2019 State of Lung Cancer Report Released

November 22, 2019 - More Americans than ever are surviving lung cancer. While the disease remains the leading cause of cancer deaths among both women and men, over the past decade, the survival rate has increased. A new report from the American Lung Association - the 2019 ...
Leggi tutto

25 Novembre 2019

ASCO Guidelines on VTE Add New Oral Agents

November 19, 2019 - Updated venous thromboembolism (VTE) guidelines issued by the American Society of Clinical Oncology (ASCO) now include the use of direct oral anticoagulants (DOACs) for patients with cancer as a preventive measure against VTE recurrence. To develop the ...
Leggi tutto

25 Novembre 2019

22 novembre 2019 – Nota Informativa Importante su metotrexato usato per il trattamento di malattie infiammatorie

22 Novembre 2019

FDA takes second action under international collaboration, approves new treatment option for patients with chronic lymphocytic leukemia

November 21, 2019 - Today, as part of Project Orbis, a collaboration with the Australian Therapeutic Goods Administration (TGA) and Health Canada, the U.S. Food and Drug Administration granted supplemental approval to acalabrutinib for the treatment of adults with chronic ...
Leggi tutto

22 Novembre 2019

FDA Accepts Application for Bevacizumab Biosimilar

November 19, 2019 - The FDA has accepted a biologics license application (BLA) for the proposed bevacizumab biosimilar SB8, according to Samsung Bioepis, the developer of the agent. Phase III findings for SB8 were presented at the 2019 ESMO Congress, in which the biosimilar ...
Leggi tutto

22 Novembre 2019

Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214

In the randomized, open-label, phase 3 CheckMate 214 trial, nivolumab plus ipilimumab (nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 wk for four doses, then nivolumab 3 mg/kg every 2 wk) had superior efficacy over sunitinib (50 mg once daily, ...
Leggi tutto

22 Novembre 2019

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC), with programmed cell death ligand 1 (PD-L1) expression associated with improved response. KEYNOTE-048 was a randomised, phase 3 study of participants with untreated locally incurable recurrent or metastatic ...
Leggi tutto

21 Novembre 2019

Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries

The Central European Cooperative Oncology Group (CECOG) and ‘ESMO Open-Cancer Horizons’ roundtable discussion brought together stakeholders from several European Union (EU) countries involved in drug development, drug authorisation and reimbursement or otherwise ...
Leggi tutto

21 Novembre 2019

18 novembre 2019 – Oggi Giornata europea della consapevolezza sugli antibiotici. AIFA lancia un quiz sui Social